Metraipolis › archive › dc_4f8f765bee87
Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer — Europe PMC PMID:41369006
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41369006
- DOI
- 10.1080/07853890.2025.2583551
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T18:41:58.474Z
- SHA-256 of the archived text
6a0683429ff43fcf6f65798c28ec6aa7745cb5e6b22e58117f13b59694c5f2b3- Stable URL of this page
https://metraipolis.com/documento/dc_4f8f765bee87
How to cite
Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer — Europe PMC PMID:41369006 — Europe PMC (en), https://europepmc.org/article/MED/41369006 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4f8f765bee87 (Metraipolis archive dc_4f8f765bee87, sha256 6a0683429ff43fcf6f65798c28ec6aa7745cb5e6b22e58117f13b59694c5f2b3)
BibTeX
@misc{dc4f8f765bee87,
title = {Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer — Europe PMC PMID:41369006},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41369006},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4f8f765bee87; sha256 6a0683429ff43fcf6f65798c28ec6aa7745cb5e6b22e58117f13b59694c5f2b3},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41369006. Agents can read the archived copy with the MCP tool read_document.